Evidence map›Paper›PMID 30374806›Full record

ReviewAdvances in therapy2018

Emerging Therapies for Inflammatory Bowel Disease.

Roni Weisshof, Katia El Jurdi, Nada Zmeter, David T Rubin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Roni WeisshofInflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA.
Katia El JurdiInflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA.
Nada ZmeterInflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA.
David T RubinInflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA. drubin@uchicago.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is a chronic heterogeneous group of diseases that has undergone major advances in the understanding of its etiology and pathogenesis in recent years. The development of biologics had resulted in better overall management of the disease, including lower rates of surgery and better long-term clinical and patient-reported outcomes. Treatment modalities have either been newly developed or extrapolated from their approved use for a different indication. Modes of action and treatment targets have varied as well. Treatments such as vedolizumab and ustekinumab, as well as second-generation corticosteroids have been approved by the US Food and Drug Administration (FDA) for the treatment of IBD. Other agents are currently being developed at various stages of clinical trials including anti-adhesion agents such as etrolizumab and abrilumab, JAK inhibitors such as tofacitinib, and anti-trafficking molecules. Toll-like receptors and phosphatidylcholine are also new promising emerging targets that are being investigated in phase 3 clinical trials. It is projected that many therapies will become available in the coming years if supported by the results of current clinical trials. This will provide IBD patients with a wide array of options and allow physicians to choose the best therapies for each individual patient.

Indexed as

AdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedFemaleGastrointestinal AgentsHumansInflammatory Bowel DiseasesMaleMiddle AgedPiperidinesProtein Kinase InhibitorsPyrimidinesPyrrolesAntibodies, Monoclonal, HumanizedGastrointestinal AgentsPiperidinesProtein Kinase InhibitorsPyrimidinesPyrrolestofacitinibCrohn’s diseaseInflammatory bowel diseaseTherapyUlcerative colitis

Identifiers

PMID30374806
PMCPMC6224002

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.